Immunicum presents a status update showing promising data for INTUVAX™ in the treatment of kidney cancer.
Read more here: Press release 130520 – Promising clinical data
Immunicum submits an application to the Medical Products Agency to initiate a clinical phase I/II-trial in liver cancer.
Read more here: Press release 130430 – HCC-application to the MPA
Immunium is presented at the Big Connect West-Day.
Read more here (in Swedish).
Immunicum’s shares start trading on NASDAQ OMX First North.
NASDAQ OMX Stockholm AB decides that Immunicum’s shares shall be traded on First North as of April 22.
Immunicum has been nominated for SwedenBIO Award which is the industry’s own price and awarded annually to prominent companies within the life science industry. An external jury selects the winner and the results are presented at SwedenBio’s Annual General Meeting on May 21.
Besides Immunicum, Affibody, Moberg Derma, GU Holding, and Oncotargeting are also nominated. This year’s award is the seventh. Last year’s winner was Vitrolife and before that, Aerocrine, BioInvent, Cellavision, Medivir and Gyros have been awarded.
The Medical Products Agency approves an additional site for recruiting patients to Immunicum’s ongoing phase I/II-studu in RCC at Norrlands Universitetssjukhus in Umeå.
Read more here (in Swedish): Pressmeddelande 130410 – Immunicum får godkänt för nytt site
Immunicum AB (publ) is one of the companies that receives funding from Sweden’s Innovation Agency program “Forska&Väx” (Research&Grow). The program aims to strengthen the competitiveness of small and medium size enterprises and create growth and renewal of Swedish industry.
Immunicum receives 470 000 SEK from the Innovation Agency, which will be used to develop the company’s manufacturing process to meet industry standards. The project will be conducted in collaboration with the Cancer Center Karolinska which is contributing with unique expertise in the manufacturing of advanced cell therapies.
See more: Pressrelease – Sweden’s Innovation Agency supports cancer vaccine
Due to the large interest in investing in Immunicum that has been shown, on March 28, 2013, the Board of Directors of the Company decided to conduct a private placement to professional investors bringing in 8,8 million SEK. This was announced in the Company’s investment memorandum for the recent listing’s issuance of 21,4 million SEK. The largest of these professional investors is LMK Forward AB.
Read more here: Pressrelease 130328 – Private placement
The Board of Immunicum AB decided on February 12, 2013 to issue new shares bringing in a total of SEK 21,4 million. The new share issue was oversubscribed. The capital that was raised will enable the completion of the ongoing clinical phase I/II-study in renal cancer, as well as the phase I/II-study in liver cancer that the Company plans.
The share issue will provide the Company with up to 890 new shareholders and the listing process on NASDAQ OMX First North may therefore also be completed according to plan with the preliminary first trading day on April 22:nd.